HPV Testing in Cervical Cancer Screening
Author Information
Author(s): van den Akker-van Marie M E, van Ballegooijen M, Rozendaal L, Meijer C J L M, Habbema J D F
Primary Institution: Erasmus MC
Hypothesis
Does adding HPV testing to cervical cancer screening extend the duration of the detectable preclinical stage?
Conclusion
Adding the HPV test to cytology in primary screening for cervical cancer results in an additional duration of the detectable preclinical stage of 2–5 years.
Supporting Evidence
- Adding the HPV test can considerably lengthen the screening interval for women with negative results.
- The cumulative incidence of CIN III was lower in women with double-negative test results.
- The study suggests that HPV testing improves the selection of women at lower risk for cervical cancer.
Takeaway
Using an HPV test along with the Pap smear can help find cervical cancer earlier and allow women to wait longer between screenings.
Methodology
The study analyzed data from a cohort of women who underwent routine screening and were followed for a mean period of 6.4 years.
Potential Biases
Potential confounding biases such as selection and length time bias may affect the results.
Limitations
The study relies on assumptions about the sensitivity of tests and may not account for all diagnostic errors.
Participant Demographics
Women aged 34–54 years.
Statistical Information
Confidence Interval
27 to 1600
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website